Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 6/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 2/20 | 0.38 |
| ▸ | FNTB | P49356 | 2/20 | 0.38 |
| ▸ | GNPAT | O15228 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12426670 | 1.00 | CA2 (0.44) | CA2CA4GAAMAPTMME | |
| SCHEMBL2551596 | 0.84 | CA2 (0.47) | CA2CA4GAAMAPTMME | |
| SCHEMBL15605968 | 0.84 | CA2 (0.47) | CA2CA4GAAMAPTMME | |
| SCHEMBL2551598 | 0.84 | CA2 (0.47) | CA2CA4GAAMAPTMME | |
| SCHEMBL31181187 | 0.81 | CA2 (0.44) | CA2CA4GAAMAPTMME | |
| SCHEMBL11940951 | 0.79 | RIPK1 (0.44) | CA2CA4GAAMAPTMME | |
| SCHEMBL12426218 | 0.79 | RIPK1 (0.44) | CA2CA4GAAMAPTMME | |
| SCHEMBL11741138 | 0.76 | CA2 (0.47) | CA2CA4GAAMAPTMME | |
| SCHEMBL11741131 | 0.76 | CA2 (0.47) | CA2CA4GAAMAPTMME | |
| SCHEMBL473070 | 0.76 | CA2 (0.47) | CA2CA4GAAMAPTMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275250-A1 | Factor Viia Inhibitor | PHARMACYCLICS, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080275250-A1 | Factor Viia Inhibitor | PHARMACYCLICS, INC. (US) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275250-A1 | Factor Viia Inhibitor | F7, F9, F5 | CA2 3522/4885CA4 2360/4885GAA 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.